Galmed Pharmaceuticals Ltd (GLMD NASDAQ) stock market data APIs
$1.5759
0.02(1.3%)
as of April 25, 2025
Galmed Pharmaceuticals Ltd Financial Data Overview
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Prev. Close
1.5759
Open
1.5927
High
1.5927
Low
1.5575
52 wk Range
1.21-15.1
Market Cap
3 658 K
Shares Outstanding
2 258 K
EPS
-1.9275
Beta
0.701
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galmed Pharmaceuticals Ltd data using free add-ons & libraries
Get Galmed Pharmaceuticals Ltd Fundamental Data
Galmed Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -6 195 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galmed Pharmaceuticals Ltd News
New
10 Oversold Global Stocks To Buy
In this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like Jul...
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
Endo International plc’s ENDP wholly owned subsidiary, Endo Ventures Limited, has entered into an agreement with Quoin Pharmaceuticals Inc. QNRX for the development, supply, commercialization and di...
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution...
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Evotec SE EVO announced that it has entered into a drug discovery collaboration deal with Janssen Pharmaceutical NV, a wholly owned subsidiary of Johnson & Johnson JNJ. According to the deal, Evotec�...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
